Anadrol and Pitavastatin Interaction

Avoid
Mechanism-based 75% confidence

Anadrol and Pitavastatin have a potentially harmful interaction with 75% confidence. Both Anadrol and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Anadrol

Oral Anabolic Steroid | Extreme Mass & Strength

Oxymetholone exerts its effects primarily through binding to the androgen receptor (AR) to promote protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme.

Half-life: ~8-9 hours Typical dose: 25-50 mg/day anabolic
androgen receptoraromataseepo receptorestrogen receptor androgenicaromatase inhibitorblood pressure raisingcarcinogenic risk
View full profile

Pitavastatin

HMG-CoA Reductase Inhibitor | Low-Interaction Statin

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface.

Half-life: ~12 hours Typical dose: 1-4 mg/day cardiovascular
aromatase aromatase inhibitorhepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Liver
moderate

Shared Safety Flags

2x 2 compounds share the aromatase-inhibitor safety flag (Anadrol, Pitavastatin). Monitor accordingly.
2x 2 hepatotoxic compounds (Anadrol, Pitavastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Anadrol, Pitavastatin). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Anadrol, Pitavastatin). Monitor accordingly.

Frequently Asked Questions

Can I take Anadrol with Pitavastatin?

Combining Anadrol with Pitavastatin is not recommended. Both Anadrol and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anadrol and Pitavastatin safe together?

This combination carries significant risk. Both Anadrol and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anadrol and Pitavastatin?

Both Anadrol and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anadrol and Pitavastatin?

Anadrol has a half-life of ~8-9 hours and Pitavastatin has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Anadrol vs Pitavastatin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.